YuanMing Capital
VC Fund
Haidian, China
YuanMing Capital is a healthcare specialty fund focusing on China-US cross border investments with offices in Beijing and New York City. The investment team has rich industry experience and a successful investment track record. The fund invests in therapeutics, medical devices, diagnostics as well as healthcare service companies based in USand/or China. We seek to bring capital and strategic resources to the future leaders of the industry.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries YuanMing Capital invests in
Stages YuanMing Capital invests in
Countries YuanMing Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 9 (50%)
- Medical 7 (39%)
- Biotechnology 7 (39%)
- Pharmaceutical 4 (22%)
- Therapeutics 3 (17%)
Stage
- Seed 4 (22%)
- Series A 4 (22%)
- Series B 3 (17%)
- Private Equity 2 (11%)
- Angel 1 (6%)
Country
- China 11 (61%)
- United States 2 (11%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Becky Chen
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Fiona Gong
Co-founding Partner
|
Co-founding Partner | Total investments: 0 | Find email | |
Lawrence Tian
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Ming Jiang
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Tina Yu
Co-Founding Partner
|
Co-Founding Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Jinze Technology
|
Jinze Technology focuses on the intelligent detection and intervention treatment of cognitive impairment diseases. | Seed / Apr 14, 2025 | |
Anjieming Medical
|
Anjieming Medical is a company that creates early glaucoma diagnosis equipment.The company's contact corneal analysis system CID employs dynamic measuring and analysis techniques. It can properly examine many biomechanical features of the cornea using dynamic changes, correct existing intraocular pressure measuring methods, acquire genuineintraocular pressure, and establish a relatively objective glaucoma index. | Seed / Nov 13, 2024 | |
Xiaochuang Medical
|
Xiaochuang Medical is an innovative medical technology company specializing in the research and development of duodenal ablation technology. | Angel / Nov 11, 2024 | |
Fengzhi Medical
|
Fengzhi Medical is committed to offering patients novel technology and platform solutions in the field of peripheral vascular intervention. | Seed / Jul 08, 2024 | |
Zisong Medical
|
Zisong Medical focuses on the research, development, and manufacturing of advanced medical-beauty photoelectric equipment, providing innovative, high-quality devices designed to support aesthetic treatments, enhance clinical effectiveness, and meet the evolving needs of the medical beauty industry. | Seed / Jan 01, 2024 | |
OneRobotics
|
OneRobotics is a technology and robotics company that designs, develops, and manufactures AI-enabled home and service robots and related software. Its products include autonomous robotic systems with machine vision and intelligent control for household tasks and interactive applications. | $5.4M / Series A / Feb 01, 2021 | |
CF PharmTech
|
CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effectivemanagement care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing. | $51M / Series F / Jul 01, 2020 | |
CANbridge Pharmaceuticals
|
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical deviceor diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia. | $98M / Series D / Feb 18, 2020 | |
Ascentage Pharma
|
Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors. | $150M / Series C / Jul 17, 2018 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $53M / Series B / Jun 26, 2018 | |
| See all 18 investments → | |||
Co-Investors
Oriza Seed Capital (Oriza Yuandian)
3 deals together
WuXi AppTec
3 deals together
HOPU Investment Management Company
2 deals together
RA Capital Management
2 deals together
3E Bioventures
1 deal together
ArrowMark Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does YuanMing Capital invest in?
YuanMing Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact YuanMing Capital?
Public channels for YuanMing Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at YuanMing Capital?
The team at YuanMing Capital includes Becky Chen (Chief Financial Officer), Fiona Gong (Co-founding Partner) and Lawrence Tian (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
